Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

✍ Scribed by Kofi Clarke; Miguel Regueiro

• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 86 KB
• Volume: 18
• Category: Article
• ISSN: 1078-0998
• DOI: 10.1002/ibd.21792

✦ Synopsis

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence-based data are lacking, the authors provide their opinion.